SARS-CoV-2 nsp13 suppresses hepatitis B virus replication by targeting cccDNA transcription
To effectively combat hepatitis B virus (HBV), it is imperative to develop potent antiviral medications targeting covalently closed circular DNA (cccDNA). Our investigation aimed to assess the impact of SARS-CoV-2 nsp13 on HBV replication across diverse HBV models, confirming its ability to significantly reduce several HBV replication markers. Additionally, our identification of the interaction between nsp13 and SMC4 opens the door for further mechanistic exploration. This marks a paradigm shift in our approach to HBV antiviral therapy, introducing an entirely novel perspective. Our findings propose a novel strategy for developing anti-HBV drugs that specifically target HBV cccDNA.
Authors
- Yuchen Xia (ORCID: https://orcid.org/0000-0001-8460-3893)
- Aixin Li (ORCID: https://orcid.org/0000-0002-3158-0170)
- Yingcheng Zheng (ORCID: https://orcid.org/0000-0002-1246-8749)
- Cheng‐Liang Zhu (ORCID: https://orcid.org/0000-0002-8285-5795)
- Qiongrong Chen (ORCID: https://orcid.org/0000-0002-6613-535X)
- Kaitao Zhao (ORCID: https://orcid.org/0000-0002-0261-1599)
- Wenbo Liu (ORCID: https://orcid.org/0000-0003-2560-0777)
- Bei Zhang (ORCID: https://orcid.org/0000-0002-2361-5492)
- Xiaoming Cheng (ORCID: https://orcid.org/0000-0002-1730-4989)
- Yurong Duan
- Lixia Hui
Institutions
- Weifang Medical University (CN)
- Wuhan University (CN)
- Hubei Provincial Center for Disease Control and Prevention (CN)
- Wuhan Institute of Virology (CN)
- Zhongnan Hospital of Wuhan University (CN)
- Renmin Hospital of Wuhan University (CN)
- State Key Laboratory of Virology
- Hubei University (CN)
Publication Details
- Journal
- Journal of Virology
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1128/jvi.01042-24
- Citations
- 2
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.77
Funders
- National Natural Science Foundation of China
- Wuhan University
- Zhongnan Hospital of Wuhan University
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities